PR99860

BASEL, Switzerland, March 30, 2023 /PRNewswire=KYODO JBN/ --

ACROBiosystems has begun to narrow its focus into helping accelerate the

process between preclinical, clinical and commercialization. With over 10 years

development, ACROBiosystems continues to surprise and bring new solutions to

the pharmaceutical industry that assists in therapeutic manufacturing and its

subsequent commercialization.

The establishment of a GMP quality management system, which upholds the strict

standards throughout preclinical and clinical manufacturing, is no easy task.

This substantial commitment is demonstrated by an investment in a GMP-grade

production facility. ACROBiosystems' GMP facility with over 180,000 sq. ft

available for manufacturing GMP products, including cytokines, enzymes, and

antibodies. ACROBiosystems also offers custom GMP-grade raw material

development starting from its targeted protein design, gene synthesis, vector

construction, protein expression, and scale-up / scale-out production services.

Operated by its subsidiary, ACROBiosystems also emphasizes the importance to

its clinical-focused strategy. ACRODiagnostics Inc. is a translational medicine

biotechnology company in the ACROBiosystems group focused on providing

analytical reagents and custom services for the clinical diagnostics industry.

ACRODiagnostics has assembled a comprehensive pathology assay development team,

including more than 10 years of experience in the diagnostic kit development

and CRO services. The ClinMax™ product line includes both biological and

clinical sample analytical kits, to help accelerate the clinical translation

and commercialization of therapies. With a product development team rich in

experience in designing, developing, and validating kits for various platforms,

products offered are ensured to be low-risk and high-quality, ideal for

clinical research.

"With our first strategic development phase success, we begin to enter the

second phase our strategic development which is to focus on more clinically

relevant applications and scale-up our manufacturing capabilities. This helps

support a large-scale, high-quality, and more localized supply chain response

to assist the needs of our clinical customers." reveals Mike Chen, Chairman and

CEO of ACROBiosystems.

ACROBiosystems was founded on customer needs and continues to support

preclinical, clinical, and commercialization efforts worldwide.

About ACROBiosystems Inc.

ACROBiosystems Group (SZ.301080) is a biotechnology company aimed at being a

cornerstone of the global biopharmaceutical and health industries by providing

products and business models innovation. The company spans across the globe and

has established numerous long-term and stable partnerships with the world's top

pharmaceutical enterprises and numerous well-known academic institutes. The

company comprises of several subsidiaries such as ACROBiosystems, bioSeedin,

Condense Capital, and ACRODiagnostics.

SOURCE  ACROBiosystems Group